Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

VentriPoint Diagnostics Ltd V.VPT

Alternate Symbol(s):  VPTDF

Technology Scientific & Technical Instruments
Ventripoint Diagnostics Ltd. is a Canada-based medical device company. It is engaged in the development and commercialization of diagnostic tools to monitor patients with heart disease. It develops a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, technically difficult imaging and cardiotoxicity in oncology patients. It provides application of artificial intelligence to echocardiography. Its flagship product, Ventripoint Medical System (VMS+), enhances echocardiography to deliver cMRI levels of accuracy for volumetric measurements and ejection fractions for all four chambers of the heart. It has developed a solution that transforms cardiac care through its 3D ECHO and MRI software. VMS products are powered by its proprietary Knowledge Based Reconstruction technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI.


TSXV:VPT - Post by User

VentriPoint Diagnostics Ltd > Zoom Call this A.M.
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(16)
•••
Comment by jopatcloon Dec 09, 2024 3:50pm
58 Views
Post# 36353382

RE:RE:Zoom Call this A.M.

RE:RE:Zoom Call this A.M. Interesting other comments also on a forum Zoom Call this A.M.

 
@cardinalthe convertibles all went to insiders essentially. They convert to stock essentially.
0
 
 
 
@Razor@Rocket67 I think it was mentioned that the 'investors' themselves requested/wanted some interest while waiting for things to develop (edited)
5
 
 
 
@cardinal2025 will have million to millions in revenue.
2
 
 
 
@Razorwould be a good question to ask (confirm/refute LOC/equity line) (edited)
4
 
 
 
@cardinali am talking 2025
4
 
 
 
@cardinalwhat is the most prestigious school in the USA?
8
 
 
 
@cardinalRocket. I am pretty sure they have large commitments next year. They do not need 20 a month right away though. For instance the Ascend deal will show workflow adoption. The dozens they sell to the top centres in the world will show need. SEimans, GE etc wont let it get too far past 100 ish. The wildcard though is valves. Worth billions if they solve (edited)
3
 
 
 
@Razorinvestor call has started - Hugh is going through financial report (from MD&A) (edited)
3
 
 
 
@Razor70+ participants (going up as people join) (edited)
3
 
 
 
@LastDanceThanks @Razor ! Keep the minutes coming
5
 
 
 
@Razor(from NR) upgrading manufacturing to match sales forecast (edited)
5
 
 
 
@Razormost of FDA response/writeup is done & awaiting 3rd party info within 2-3 weeks
1
 
 
 
@yudiHarvard University =1 Johns Hopkins University=2 University of Toronto =3 in best medical school in the world
5
 
 
 
@Razorawaiting to close UK sales soon + future prospects + 18 AngioPro demos in 2025 (edited)
2
 
 
 
@JSSRDoes that mean they don’t have to wait for financing to submit the additional requirements for FDA review/approval?
4
 
 
 
@Razorlist price will increase after FDA clearance
4
 
 
 
@cardinalUK has roughly 50 next year
2
 
 
 
@cardinalhe said several dozen additonal to the 18
1
 
 
 
@Razor2025 outlook: geometric growth in coming years..... heaviy dependant on capital
2
 
 
 
@cardinalThey've identified that once at demo it is essentially done. The pre qualification to the point has already established the client wants the product
2
 
 
 
@cardinaland can afford it
5
 
 
 
@Razorcapital financing update within 1-2 days (debentures) (edited)
4
 
 
 
@cardinaladditional units to mayo
3
 
 
 
@cardinalGE discussions ongoing
4
 
 
 
@Razorassuming enough capital, will increase USA sales to team from 1 to 3
3
 
 
 
@cardinalAscend will be quick US sales
4
 
 
 
@RazorWill be licensing model with Ascend so VPT will evolve to mix of direct sales $ licensing...
4
 
 
 
@Razorwants to cut # on-site visits/training from multiple to 1 (& use more virtual) (edited)
4
 
 
 
@Razorvalves would be transformational (avoid transesophageal echo) (edited)
4
 
 
 
@cardinalvalves are billions. Europe a week ago
3
 
 
 
@Razorlarger financing in Q1
4
 
 
 
@Razoraiming for 2026 for cash flow even
4
 
 
 
@Razorsounds like Q1 might be busy with NRs
3
 
 
 
@Razorcannot market VMS 4,0 before FDA approval but theres word of mouth  (edited)
3
 
 
 
@Razor@Investor765 thats what it sounds like
4
 
 
 
@RazorHugh is expanding on 3rd party info...
4
 
 
 
@Razor1 is penetration test (hacking) - VMS system was sentto them
5
 
 
 
@cardinalrochester alone likely takes two dozen. They love th eproduct and its very inexpesive in their world. They have additonal in front of them now
4
 
 
 
@cardinalHugh wont say it but, customers feel much more comfortable with the structure hes created and his understanding of the realationships
3
 
 
 
@Razorrecording will be available on the VPT website
0
 
 
 
@JohnnyUtahThanks for relaying info, I was unable to make the call, but will be listening to the recording when I get a chance.
2
 
 
 
@Razorinvitation to contact him directly if interested in participating in debentures
2
 
 
 
@yudi@cardinal & @Razor Many thanks for sharing your comments from this meeting.
2
 
 
 
@Razortoo bad I'm out of $$ at the moment - I'd definitely participate. Anyone know what the minimum amount is to participate in debentures? (edited)
2
 
 
 
@Razorthx @hassy @Investor765
7
 
 
 
@GoldOxThis is going to see a reversal as soon as news comes out and this will run. I predict $0.30+ by end of January. The sector always performs this way. Huge dip and new investors buy at a discount and carry this up like a second wind.  (edited)
0
 
 
 
@yudiInteresting Revolutionizing Cardiac Nuclear Medicine: From Disconnection to Integration ASCEND Cardiovascular 9 dcembre 2024 https://www.linkedin.com/pulse/revolutionizing-cardiac-nuclear-medicine-from-disconnection-aelyc/?trackingId=K%2B6VfyoMtLR%2B8WKUSR%2FSzg%3D%3D
0
 
 
 
@yudi13:35 R 0,105 on TSX-V
5
 
 
 
@cardinalAgain The current converts have all gone to insiders who will convert to shares. They know what they own
 
@cardinalthe convertibles all went to insiders essentially. They convert to stock essentially.
0
 
 
 
@Razor@Rocket67 I think it was mentioned that the 'investors' themselves requested/wanted some interest while waiting for things to develop (edited)
5
 
 
 
@cardinal2025 will have million to millions in revenue.
2
 
 
 
@Razorwould be a good question to ask (confirm/refute LOC/equity line) (edited)
4
 
 
 
@cardinali am talking 2025
4
 
 
 
@cardinalwhat is the most prestigious school in the USA?
8
 
 
 
@cardinalRocket. I am pretty sure they have large commitments next year. They do not need 20 a month right away though. For instance the Ascend deal will show workflow adoption. The dozens they sell to the top centres in the world will show need. SEimans, GE etc wont let it get too far past 100 ish. The wildcard though is valves. Worth billions if they solve (edited)
3
 
 
 
@Razorinvestor call has started - Hugh is going through financial report (from MD&A) (edited)
3
 
 
 
@Razor70+ participants (going up as people join) (edited)
3
 
 
 
@LastDanceThanks @Razor ! Keep the minutes coming
5
 
 
 
@Razor(from NR) upgrading manufacturing to match sales forecast (edited)
5
 
 
 
@Razormost of FDA response/writeup is done & awaiting 3rd party info within 2-3 weeks
1
 
 
 
@yudiHarvard University =1 Johns Hopkins University=2 University of Toronto =3 in best medical school in the world
5
 
 
 
@Razorawaiting to close UK sales soon + future prospects + 18 AngioPro demos in 2025 (edited)
2
 
 
 
@JSSRDoes that mean they don’t have to wait for financing to submit the additional requirements for FDA review/approval?
4
 
 
 
@Razorlist price will increase after FDA clearance
4
 
 
 
@cardinalUK has roughly 50 next year
2
 
 
 
@cardinalhe said several dozen additonal to the 18
1
 
 
 
@Razor2025 outlook: geometric growth in coming years..... heaviy dependant on capital
2
 
 
 
@cardinalThey've identified that once at demo it is essentially done. The pre qualification to the point has already established the client wants the product
2
 
 
 
@cardinaland can afford it
5
 
 
 
@Razorcapital financing update within 1-2 days (debentures) (edited)
4
 
 
 
@cardinaladditional units to mayo
3
 
 
 
@cardinalGE discussions ongoing
4
 
 
 
@Razorassuming enough capital, will increase USA sales to team from 1 to 3
3
 
 
 
@cardinalAscend will be quick US sales
4
 
 
 
@RazorWill be licensing model with Ascend so VPT will evolve to mix of direct sales $ licensing...
4
 
 
 
@Razorwants to cut # on-site visits/training from multiple to 1 (& use more virtual) (edited)
4
 
 
 
@Razorvalves would be transformational (avoid transesophageal echo) (edited)
4
 
 
 
@cardinalvalves are billions. Europe a week ago
3
 
 
 
@Razorlarger financing in Q1
4
 
 
 
@Razoraiming for 2026 for cash flow even
4
 
 
 
@Razorsounds like Q1 might be busy with NRs
3
 
 
 
@Razorcannot market VMS 4,0 before FDA approval but theres word of mouth  (edited)
3
 
 
 
@Razor@Investor765 thats what it sounds like
4
 
 
 
@RazorHugh is expanding on 3rd party info...
4
 
 
 
@Razor1 is penetration test (hacking) - VMS system was sentto them
5
 
 
 
@cardinalrochester alone likely takes two dozen. They love th eproduct and its very inexpesive in their world. They have additonal in front of them now
4
 
 
 
@cardinalHugh wont say it but, customers feel much more comfortable with the structure hes created and his understanding of the realationships
3
 
 
 
@Razorrecording will be available on the VPT website
0
 
 
 
@JohnnyUtahThanks for relaying info, I was unable to make the call, but will be listening to the recording when I get a chance.
2
 
 
 
@Razorinvitation to contact him directly if interested in participating in debentures
2
 
 
 
@yudi@cardinal & @Razor Many thanks for sharing your comments from this meeting.
2
 
 
 
@Razortoo bad I'm out of $$ at the moment - I'd definitely participate. Anyone know what the minimum amount is to participate in debentures? (edited)
2
 
 
 
@Razorthx @hassy @Investor765
7
 
 
 
@GoldOxThis is going to see a reversal as soon as news comes out and this will run. I predict $0.30+ by end of January. The sector always performs this way. Huge dip and new investors buy at a discount and carry this up like a second wind.  (edited)
0
 
 
 
@yudiInteresting Revolutionizing Cardiac Nuclear Medicine: From Disconnection to Integration ASCEND Cardiovascular 9 dcembre 2024 https://www.linkedin.com/pulse/revolutionizing-cardiac-nuclear-medicine-from-disconnection-aelyc/?trackingId=K%2B6VfyoMtLR%2B8WKUSR%2FSzg%3D%3D
0
 
 
 
@yudi13:35 R 0,105 on TSX-V
5
 
 
 
@cardinalAgain The current converts have all gone to insiders who will convert to shares. They know what they own

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities